Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection-Reference-Cited by-同舟云学术

Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection

Published:2024-04 Issue:2 Volume:22 Page:599-609.e2
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Tiruye Tenaw^ORCID,O'Callaghan Michael,FitzGerald Liesel M.^ORCID,Moretti Kim,Jay Alex,Higgs Braden,Kichenadasse Ganessan,Caughey Gillian,Roder David,Beckmann Kerri

Funder

Movember Foundation

Publisher

Elsevier BV

Reference32 articles.

1. Australian Institute of Health and Welfare. Cancer data in Australia. Available at: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/overview-of-cancer-in-australia-2023 Accessed August 31, 2023.

2. Association of Comorbidity, Age, and Radical Surgical Therapy for Prostate Cancer, Bladder Cancer, and Renal Cell Carcinoma;Adejoro;Urology,2016

3. Review of methods used to measure comorbidity in cancer populations: no gold standard exists;Sarfati;J Clin Epidemiol,2012

4. The changing prevalence of comorbidity across the age spectrum;Piccirillo;Crit Rev Oncol Hematol,2008

5. Prognostic value of comorbidity measures among Australian men with non-metastatic prostate cancer;Tiruye;Cancer Epidemiol,2023

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporal trends in medication and service use patterns for mental health issues among men with prostate cancer;Psycho-Oncology;2024-07

2. Impact of comorbidities on prostate cancer‐specific mortality: A population‐based cohort study;The Prostate;2024-05-26